Crossmark

The Advantages of FEV1 Percent Predicted Change During Bronchial Challenge Testing

Published Online: 2025-07-05

Published Print: 2025-12

Authors

Dean, James https://orcid.org/0000-0003-1657-3885
Beech, Augusta

Singh, Dave
License Information

Text and Data Mining valid from 2025-07-05

Version of Record valid from 2025-07-05
More Information

Article History

Received: 11 February 2025

Accepted: 24 May 2025

First Online: 5 July 2025

Declarations

:

: Author JD and AB declare that they have no financial interests. Author DS has received personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Epidendo, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Kinaset, Menarini, Novartis, Orion, Pulmatrix, Sanofi, Synairgen, Teva, Theravance and Verona.

: Informed consent was obtained from all individual participants included in the study.

: Not applicable.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted for study protocols by North West—Greater Manchester East Research Ethics Committee (05/Q1402/41; 14/NW/0048; 12/NW/0632) and North Manchester Research Ethics Committee (08/H1006/54).

Document is current